Oncternal Therapeutics Inc (NASDAQ:ONCT)’s traded shares stood at 0.45 million during the last session, with the company’s beta value hitting 1.46. At the close of trading, the stock’s price was $1.46, to imply a decrease of -14.12% or -$0.24 in intraday trading. The ONCT share’s 52-week high remains $13.14, putting it -800.0% down since that peak but still an impressive 0.0% since price per share fell to its 52-week low of $1.46. The company has a valuation of $4.32M, with an average of 70870.0 shares in intraday trading volume over the past 10 days and average of 18.60K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Oncternal Therapeutics Inc (ONCT), translating to a mean rating of 1.67. Of 6 analyst(s) looking at the stock, 0 analyst(s) give ONCT a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 6 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -3.0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Oncternal Therapeutics Inc (NASDAQ:ONCT) trade information
After registering a -14.12% downside in the last session, Oncternal Therapeutics Inc (ONCT) has traded red over the past five days. The 5-day price performance for the stock is -63.32%, and -63.95% over 30 days. With these gigs, the year-to-date price performance is -86.39%. Short interest in Oncternal Therapeutics Inc (NASDAQ:ONCT) saw shorts transact 13541.0 shares and set a 1.18 days time to cover.
The extremes give us $28 and $28 for target low and target high price respectively. As such, ONCT has been trading -1817.81% off suggested target high and -1817.81% from its likely low.
Oncternal Therapeutics Inc (ONCT) estimates and forecasts
Looking at statistics comparing Oncternal Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Oncternal Therapeutics Inc (ONCT) shares are -83.87% down over the last 6 months, with its year-to-date growth rate lower than industry average at 14.89% against 19.70%. Revenue is forecast to grow 11.80% this quarter before jumping 12.20% for the next one. The rating firms project that company’s revenue will grow 115.30% compared to the previous financial year.
Revenue forecast for the current quarter as set by 3 analysts is 160k. Meanwhile, for the current quarter, a total of 3 analyst(s) estimate revenue growth to 160k.Earnings reports from the last fiscal year show that sales brought in 179k and 297k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -10.60% before dropping -46.10% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 18.19% for the past 5-year period. While 2024 is set for a 15.12% return in earnings, projections for the next 5 years are at 0.00% annually.
ONCT Dividends
Oncternal Therapeutics Inc has its next earnings report out on 2024-Nov-07. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Oncternal Therapeutics Inc (NASDAQ:ONCT)’s Major holders
Oncternal Therapeutics Inc insiders hold 9.23% of total outstanding shares, with institutional holders owning 16.33% of the shares at 17.99% float percentage. In total, 16.33% institutions holds shares in the company.
